Virtual Library

Start Your Search

Hiroshi Haneda



Author of

  • +

    OA11 - Thymic and Other Thoracic Tumours: Targeted Therapies, Biomarkers and Neo/Adjuvant Radiotherapy (ID 919)

    • Event: WCLC 2018
    • Type: Oral Abstract Session
    • Track: Thymoma/Other Thoracic Malignancies
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/25/2018, 13:30 - 15:00, Room 205 BD
    • +

      OA11.04 - A Comparative Study of PD-L1 Immunohistochemical Assays with Four Reliable Antibodies in Thymic Carcinoma (ID 12114)

      14:05 - 14:15  |  Author(s): Hiroshi Haneda

      • Abstract
      • Presentation
      • Slides

      Background

      Currently, programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) targeted therapy has not been established for thymic carcinoma (TC) yet, and limited information is available regarding the expression pattern of PD-L1 in TC. Four immunohistochemical assays are registered with the US Food and Drug Administration to detect the expression of PD-L1. We investigated the PD-L1 expression in thymic carcinomas using these four diagnostic assays.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      The clinicopathological data of 53 TC patients were reviewed and their specimens were subjected to four PD-L1 assays with different antibodies (22C3, 28-8, SP142, and SP263). We examined tumor proportion scores (TPS) in each case and the cutoff values were settled at 1% for 22C3, 1% for 28-8, 1% for SP142, and 25% for SP263. Date were correlated to clinicopathologic parameters and outcomes.

      4c3880bb027f159e801041b1021e88e8 Result

      The study population included 32 male patients and 21 female patients (median age, 61 years). In the TPS, the four assays showed similar scores in each case. Pairwise analyses of the TPS for the four assays showed high concordance among the four assays (the Spearman’s rank correlation coefficients were all >0.9). Histopathologically, high TPS was observed in squamous cell carcinomas (SqCCs). Using cutoffs, 34 cases (64.2%) with 22C3, 41 cases (77.4%) with 28-8, 43 cases (81.1%) with SP142, and 26 cases (49.1%) with SP263 were detected as PD-L1 positive. In SqCCs, the high expression of PD-L1 (TPS ≥50%) were associated with early stage cancer when evaluated with 22C3 (p=0.0205), 28-8 (p=0.0448), and SP263 (p=0.0486), respectively. However the high expression of PD-L1 were not associated with sex, age, tumor size, and curability. The SqCC patients with high expression of PD-L1 tended to show longer overall survival; p=0.0250 in 22C3, p=0.0719 in 28-8, p=0.1064 in SP142, and p=0.0675 in SP263.

      8eea62084ca7e541d918e823422bd82e Conclusion

      The present study revealed that the TC patients, especially SqCC patients, showed high PD-L1 positivity and that the staining pattern showed high concordance among the four assays. High expression of PD-L1 might be a prognostic predictor, though observed effect was independent on the assay. Our results suggest that the PD-1/PD-L1 pathway is a potential immunotherapeutic target in TC.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P2.06 - Mesothelioma (Not CME Accredited Session) (ID 955)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P2.06-37 - Four Immunohistochemical Assays to Measure the PD-L1 Expression in Malignant Pleural Mesothelioma (ID 11757)

      16:45 - 18:00  |  Author(s): Hiroshi Haneda

      • Abstract
      • Slides

      Background

      Malignant pleural mesothelioma (MPM) is a rare disease with no effective standardized systemic therapy. Immune checkpoint inhibitors (ICIs) targeting the programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) pathway are expected to be a novel therapy for MPM patients. However, the PD-L1 expression, which is a predictor of the response to ICIs, is unclear in MPM.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      We studied the PD-L1 expression using four immunohistochemical, companion diagnostic assays (SP142, SP263, 28-8 and 22C3) in 32 MPM patients. The PD-L1 expression in tumor cells (TCs) and immune cells (ICs) was evaluated to clarify the rate of PD-L1 expression and the concordance among the four assays in MPM. The cut-off values were set at 1% TC or 1% IC for SP142, 25% TC for SP263, 1% TC for 28-8, and 1% TC for 22C.

      4c3880bb027f159e801041b1021e88e8 Result

      The positivity rate of PD-L1 expression was 53.1% for SP142, 28.1% for SP263, 53.1% for 28-8, and 56.3% for 22C3. Nine cases were positive and 10 were negative for all assays. Discordance among the four assays was found in 13 cases. The concordance rates between SP142 and 22C3 and between 28-8 and 22C3 were the highest (84.4%). The concordance rates between SP263 and the other three assays were low (71.9% to 75.0%). 000001.jpg

      8eea62084ca7e541d918e823422bd82e Conclusion

      The PD-L1 expression in MPM was almost equivalent for three of the assays. Given the cut-off values set in our study, these findings suggested that these assays, except for SP263, can be used for accurate PD-L1 immunostaining in MPM.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P3.16 - Treatment of Early Stage/Localized Disease (Not CME Accredited Session) (ID 982)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
    • +

      P3.16-37 - Comparison of Long-Term Outcomes Between VATS and Open Lobectomies for Stage I NSCLC: Propensity Score-Matching Analysis (ID 12101)

      12:00 - 13:30  |  Author(s): Hiroshi Haneda

      • Abstract
      • Slides

      Background

      Video-assisted thoracoscopic surgery (VATS) lobectomy is widely spread for patients with clinical stage I non-small cell lung cancer (NSCLC). The postoperative survival and safety of VATS lobectomy are reported equal or better than those of open lobectomy.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      We retrospectively reviewed the clinical data of 186 patients underwent lobectomy with clinical and pathological stage IA NSCLC from January 2008 to December 2013. Perioperative clinical factors and outcomes of patients with clinical and pathological stage IA NSCLC who underwent lobectomy were compared between VATS (n=63) and thoracotomy (n=123) using a propensity score-matching analysis.

      4c3880bb027f159e801041b1021e88e8 Result

      In the analysis of 61 matched cases, the VATS group showed decreased blood loss and lower value of the C-reactive protein (CRP) at the peak, despite longer operative time. The VATS group demonstrated a significant longer survival, despite greater number of preoperative comorbidities than the thoracotomy group. The 5-year overall survival (OS) of VATS and thoracotomy were 100% and 89% each (log-rank p=0.02). The 5-year disease-free survival (DFS) of VATS and thoracotomy were 100% and 81% in each (log-rank p<0.01).

      8eea62084ca7e541d918e823422bd82e Conclusion

      The results of this study indicate that VATS has some advantages compared with thoracotomy in early stage lung cancer patients.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.